MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/1545-5017.70624

Медицинская библиотека · Pediatric blood & cancer · 2026

Infant Embryonal CNS Tumors: Molecular Insights and Treatment Considerations for Contemporary Pediatric Neuro-Oncology.

Damodharan Sudarshawn, Wright-Nadkarni Mariah, Abdelbaki Mohamed S, Dhall Girish

СтатьяОбзорПеревод в очереди

Аннотация

BACKGROUND

Embryonal tumors comprise the majority of malignant central nervous system (CNS) neoplasms diagnosed in children under 3 years of age. Compared with their counterparts in older children, these tumors exhibit distinct molecular biology and a more aggressive clinical phenotype, while their management is complicated by the heightened vulnerability of the developing brain to acute toxicity and long-term sequelae from surgery, chemotherapy, and radiotherapy.

OBJECTIVES

To summarize the contemporary understanding of infant CNS embryonal tumors, including molecular classification, treatment paradigms, and emerging therapeutic strategies, and to outline a framework for molecularly driven, risk-adapted management.

DESIGN AND

METHODS

We performed a narrative review of published cooperative-group, consortium, and single-institution trials in medulloblastoma, atypical teratoid/rhabdoid tumor (AT/RT), embryonal tumor with multilayered rosettes (ETMR), pineoblastoma, and other infant CNS embryonal entities, integrating findings with the 2021 WHO Classification of CNS Tumors and recent DNA methylation- and next-generation sequencing-based subclassifications.

RESULTS

Molecular profiling has reshaped diagnosis and risk stratification across all infant embryonal entities, identifying clinically actionable subgroups (e.g., SHH-I/II in medulloblastoma; AT/RT-TYR, -SHH, -MYC; ETMR with C19MC or DICER1 alterations; pineoblastoma molecular subgroups). Multimodal regimens that delay or avoid craniospinal irradiation have achieved durable survival in favorable-risk SHH-activated medulloblastoma, while outcomes remain poor for Group 3 medulloblastoma, ETMR, pineoblastoma, and metastatic AT/RT. Investigational targeted and immunotherapeutic strategies, intraventricular methotrexate, proton-beam radiotherapy, and cerebrospinal fluid liquid biopsy are increasingly being incorporated into risk-adapted approaches.

CONCLUSION

Molecularly driven, risk-adapted clinical trials and international collaborative registries are essential to advance care for infants with CNS embryonal tumors, with the dual goals of improving survival and reducing treatment-related neurodevelopmental morbidity.

Для цитирования: Damodharan Sudarshawn, Wright-Nadkarni Mariah, Abdelbaki Mohamed S, Dhall Girish. Infant Embryonal CNS Tumors: Molecular Insights and Treatment Considerations for Contemporary Pediatric Neuro-Oncology.. Pediatric blood & cancer. 2026. DOI: 10.1002/1545-5017.70624.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.